Akero's NASH Treatment Fails, Stock Plummets
TL;DR
Shares of Akero Therapeutics (AKRO) and 89bio (ETNB) plummeted after Akero's liver-disease treatment failed to meet expectations in a midstage study. While the drug showed statistically significant results in resolving NASH, the improvement in liver scarring was not statistically significant. Despite this, analysts believe that the effectiveness data sets for both companies are strong, with 89bio potentially pulling ahead due to its dosing schedule and lower side effects. Akero shares fell 64% and 89bio shares tumbled 36.6% as a result of the news.
Topics:businesshealthcare#89bio#akero-therapeutics#healthcare#liver-disease-treatment#nash#stock-market
- AKRO Stock Plummets, Dragging Down ETNB Stock, On Liver-Disease Flop Investor's Business Daily
- Biggest stock movers today: Coherent, Truist Financial, Akero Therapeutics and more (COHR) Seeking Alpha
- Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization an GlobeNewswire
- Akero's treatment for NASH falls short in cirrhosis study STAT
- Akero stock plummets after mid-stage data for NASH candidate Seeking Alpha
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Investor's Business Daily